May 26, 2023, 3:10 PM EDT
In the latest episode of Brad Hightower's Note to File Podcast, Lokavant CEO Rohit Nambisan engaged in an enlightening conversation about the evolution of clinical trials. The discussion was...
What people are saying about Lokavant
In the latest episode of Brad Hightower's Note to File Podcast, Lokavant CEO Rohit Nambisan engaged in an enlightening conversation about the evolution of clinical trials. The discussion was...
The year 2020 was a watershed moment for many reasons, but notably, it cast a light on the pervasive health and social inequities that have long marred the U.S. The COVID-19 pandemic hit diverse...
A data-agnostic integration platform for optimizing trial planning and conduct hit the streets three years ago, bringing near-real-time insights about every participant, site, country, region, and...
NEW YORK – April 26, 2023 – Lokavant, the clinical trial intelligence platform company, today announced its Product Advisory Board. This esteemed group of industry leaders will help drive the...
Recently Rohit Nambisan the CEO of New York City-based Lokavant connected with TrialSite’s founder Daniel O’Connor for a review of the startup’s origins, emerging value proposition and directions....
Lokavant is a company looking to fix the fragmentation problem in clinical trials, which has been caused by the number of trials nearly quadrupling since 2010, leading to far more data being...
NEW YORK – April 4, 2023 – Lokavant, the clinical trial intelligence platform company, announces strategic new hires to drive its mission to make clinical trials smarter. Lokavant, launched in 2020,...
Investment will transform the clinical research industry for smarter and faster trials.
The combination of data and analytics will accelerate pharmaceutical breakthroughs by helping clinical trial teams uncover the best sites and investigators for their trials.